ReviewPsoriasis (Auckland, N.Z.)2024
Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review.
Review in Psoriasis (Auckland, N.Z.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation.Frontiers in endocrinology · 2026Trial
- Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making.EClinicalMedicine · 2026Review
- Efficacy of glucagon-like peptide 1 analogues in psoriasis: A cohort study.JAAD international · 2026Article
- Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report.JAAD case reports · 2026Article
- Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review.Journal of clinical medicine · 2026Review
- The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Psoriasis and Hidradenitis Suppurativa.The Journal of clinical and aesthetic dermatology · 2026Review
- Mechanisms of Glucagon-Like Peptide 1 Receptor Agonist-Induced Facial Lipodystrophy and a Path Toward Prevention.Journal of cosmetic dermatology · 2025Article
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons.Dermatology and therapy · 2025Review
- GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.European journal of clinical pharmacology · 2025Review
- Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications.Skin appendage disorders · 2025Review
- Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025).Pharmaceutics · 2025Review
- Cardiovascular disease risk in psoriatic disease: mechanisms and implications for clinical practice.Current opinion in rheumatology · 2025Review
- A Closer Look at the Dermatological Profile of GLP-1 Agonists.Diseases (Basel, Switzerland) · 2025Review
- Skin Microbiota: Mediator of Interactions Between Metabolic Disorders and Cutaneous Health and Disease.Microorganisms · 2025Review
- Psoriasis: an emerging risk factor for ischemic stroke?Frontiers in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is an immune-mediated skin disease known to be associated with a higher risk of cardiometabolic comorbidities such as hypertension, myocardial infarction, and stroke. GLP-1 receptor agonists (GLP-1RAs) are medications approved to treat type 2 diabetes mellitus and obesity and have been reported to improve psoriasis. As more psoriasis patients start GLP-1RAs for approved indications, it is of interest to understand the impact of GLP-1RAs on both psoriasis and associated cardiovascular risk. In this review, we examine the effect of GLP-1RAs on psoriasis and cardiovascular comorbidities-defined as hypertension, stroke, and myocardial infarction. The majority of case reports and prospective cohort studies found GLP-1RAs improved psoriasis, while two randomized controlled trials showed conflicting results. For cardiovascular disease, most studies found GLP-1RAs reduced systolic blood pressure, total stroke, and myocardial mortality. These results suggest that GLP-1RAs may be a particularly promising treatment for psoriasis patients with diabetes or obesity comorbidities, offering both cardioprotective benefits and potential improvement in psoriatic symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.